







Post-Event Report

# MENASO

CEREBROVASCULAR GRAND ROUND

webinar

18 May 2021

8:00 PM - 09:30 PM (Dubai Time)



Supported By:



Medtronic Further, Together Managed By:





#### **EVENT SUMMARY**

# 5th CEREBROVASCULAR GRAND ROUND Webinar, 18 May 2021

The 5th chapter of the great Cerebrovascular Grand Round Webinar, held under the auspices of the **MENA STROKE Organization**, **American Stroke Association**, and **World Stroke Organization**, and supported by Boehringer Ingelheim and Medtronic, was a unique session to provide comprehensive education about Intracerebral hemorrhage (ICH) and its latest treatments, therapeutic strategies, pathophysiology, complications, and management. It revealed the updates in diagnosis and treatments of the condition. The webinar has helped 272 delegates from 31 countries around the world.

Webinar Chairmen Dr. Suhail Abdulla Alrukn, President of MENASO and Consultant Neurology Rashid at Hospital, UAE, and Dr. Tareq Almaghrabi has appointed the panel of speakers that include Prof. Dr. Edward C Jauch, Chief of System Research and Adjunct Professor at Mission Research Institute (Mission Health Department System), Emergency Medicine, Medical University of South Carolina, and Departments of Emergency Medicine and Neurology, University of North Carolina, and Prof. Kiwon Lee, MD, FACP, FAHA, FCCM, Professor of Neurology and Neurosurgery and Chief of Neurology Service, Director of Comprehensive Stroke Center. Director of Stroke and Critical Care Neuro Division. and Director of Intensive Care Unit at Rutgers,

The State University of New Jersey and Robert Wood Johnson University Hospital.

**Dr. Suhail Abdulla Alrukn** has delivered the opening remarks and introduced the speakers. Webinar chairman **Dr. Tareq Almaghrabi** has welcomed both the speakers and attendees to the session.

Prof. Dr. Edward C Jauch's lecture was focused on ICH pathophysiology complications, and where he explained the of management Intracerebral Hemorrhage in 2021. He started the presentation with a short background of the condition, sites of spontaneous ICH, risk factors and ICH etiology. He stated that COVID infection is associated with increased



risk of ischemic stroke and venous sinus thrombosis and the mortality rate is exceptionally high for the patients with COVID and ICH. His lecture has educated the delegates about pathophysiology of injury, ACH progression, prognosis and therapeutic targets, imaging, treatments, and ICH management.

Webinar Chairman **Dr. Tareq Almaghrabi** has conducted the Q&A session and webinar chairman Dr. Suhail Abdulla Alrukn has expressed his appreciation thanked the attendees for their participation.

**Prof. Kiwon Lee's** lecture was centered on Therapeutic Options for ICH:

MAP, ICP, CPP and Evacuation. He discussed spontaneous, non-traumatic ICH with no underlying vascular abnormalities and shared his experiences on different cases. He explained situation based facts, treatment options, and medications and stressed the importance of having data before deciding more treatment protocol. Prof. Kiwon has quoted the relationships between blood pressure (BP) and intracranial pressure (ICP) with the help of graph and statistical data. He also shared his on CPP, CBP, knowledge Vasoreactivity before he ends the session.





# SPEAKERS







#### Dr. Tareq Almaghrabi

Vascular Neurologist and Neurointensivist, Neurology Assistant Professor, University of Tabuk, KSA



#### **SPEAKERS**

# Speaker



#### Dr. Edward Jauch C. MD MS

Chief of System Research Mission
Research Institute
(Mission Health System)
Adjunct Professor,
Department of Emergency Medicine,
Medical University of South Carolina
Departments of Emergency Medicine
and Neurology, University of North Carolina

## Speaker



#### Prof. Kiwon Lee, MD, FACP, FAHA, FCCM

Professor of Neurology and Neurosurgery
Chief of Neurology Service
Director, Comprehensive Stroke Center
Director, Stroke and Critical Care Division
Director, Neuro Intensive Care Unit
Rutgers, The State University of New Jersey
Robert Wood Johnson Medical School
Robert Wood Johnson University Hospital



## DELEGATE INFORMATION

## Participating Country

Egypt

Bahrain

United Arab Emirates

Malaysia

Saudi Arabia

Sri Lanka

Kuwait

Panama

Palestine, State of

Iraq

South Africa

India

Morocco

United States

Jordan

Indonesia

**Hearth State** United Kingdom

**≒** Kenya

**Macedonia** 

Lebanon

Tunisia

Namibia

Botswana

🚺 Algeria

Aruba

Mauritius

Philippines

Qatar

Azerbaijan

★ Viet Nam

Libya



Number of Attendees

804



Number of Speakers

3





# Webinar Gallery







1



# Webinar Gallery







Dr. Edward Jauch

1



#### QUESTION & ANSWER SESSION

- A 60-year-old woman with unremarkable PMHx (not HTN) developed Occipital lobar ICH 7 days after 1st dose of COVID19 vaccine, CTA and DSA normal, vasculitis screen came -ve, can COVID19 be the cause of this bleed? Would u recommend the second dose or you withhold it, she was discharged with no deficit?
- There are some families of antihypertensive therapy that increase the risk of ICH?
- What mechanisms made a bleeding stop during cerebral hematoma? And what is the duration of bleeding during cerebral hematoma (seconds or minutes)?
- PCC is preferred when the patient is under warfarin?
- What is the guideline or the expert experience in managing ICH associated with AF either valvular or non-valvular AF? When to start anticoagulation and what about ICH with patients with prosthetic metallic valves on warfarin with the risk of stag valve development?
- What about reintroduction of anticoagulant after cerebral hematoma in patients with AFib?
- A common issue with ICH cases is the reintroduction delay of Anticoagulation if needed like mechanical valve or other obligatory indication. Do you use ICH score to decide or something else?



- You note alcohol as a risk factor for ICH. Is it binge drinking with resultant acute ICH or is it a certain duration and amount of drinking alcohol that precipitates ICH and if so, how much and for how long?
- Is there any indication for prophylactic anti-seizure in large volume asymptomatic ICH? if yes, for how long anti-seizure can be used?
- For patients with later Ischaemia risk, how soon to start Anticoagulation?
- Is centrum semiovale ICH considered HT bleeding and if not it should be investigated for other causes?
- What is the prognosis of medially placed intracerebral hemorrhage with intraventicular extension, as may happen in thalamus hemorrhage?
- "Centrally-driven sensory disturbances" What does that mean? Please elaborate.
- I lost a patient of 80 years old, yesterday, HBP on medication, he was hospitalized Sunday for acute ischemic stroke, with normal first CT scan, 48hours later, coma, high blood pressure 220/120, Second CT scan, massive ICH?
- Criteria for a patient where EVD insertion is a must. Is there a cutoff point for conscious level or hematoma size or other criteria?
- In aneurysmal ICH, with another Aneurysm, when is the appropriate time to operate or clip, or coil?
- Recurrent lobar ICH in 70 years in less than one month can give hint to the diagnosis weather cerebral amyloidosis or Hg met or other causes?



- How bad is the risk of CNS infection with EVD insertion and is there any prophylactic measure during surgery (a technique) or after surgery.
   Is prophylactic antibiotic needed?
- How we deal with Apixpan and haemorrhagic transformation ischemic stroke?
- I have a case of post vaccinations covid. How we treat it?
- What about the management of post anti thrombotic hemoharrgic stroke?

# Post-Event Report MENASO CEREBROVASCULAR GRAND ROUND Webing

For more information, please contact:

#### **Abrar Mohammed Abuelkhair**

MENASO Secretary secretary@menastroke.org M. +971 55 248 8353 • T. + 971 2658 8717 Website: http://menastroke.org